Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID-19 pandemic.
Sema Koç YıldırımNeslihan Demirel ÖğütEce ErbağcıPublished in: Journal of cosmetic dermatology (2022)
As a result, our findings have shown that omalizumab treatment in CSU patients during the COVID-19 pandemic does not increase the risk of COVID-19 infection and omalizumab can be used safely.